Product Description
Alfentanil is a synthetic short-acting opioid with analgesic and local anesthesia enhancing activity. Alfentanil primarily binds to mu-opioid receptor, a G-protein-coupled receptor, thereby mimicking the actions of morphine, the prototypical mu receptor agonist. This agent induces anti-nociception responses mediated through inhibiting the release of various neurotransmitters such as substance P, GABA, dopamine, acetylcholineand noradrenaline; in addition, the release of vasopressin, somatostatin, insulin and glucagon are also inhibited. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Alfentanil)
Mechanisms of Action: CYP3A Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Australia | Austria | Belgium | Brazil | Canada | Chile | Czech | Denmark | Egypt | Finland | France | Germany | Greece | Hong Kong | Ireland | Italy | Korea | Latvia | Luxembourg | Malaysia | Malta | Morocco | Netherlands | New Zealand | Norway | Peru | Portugal | Saudi Arabia | Serbia | Singapore | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | Tunisia | Turkey | United Arab Emirates | United Kingdom | United States | Venezuela | Vietnam
Approved Indications: Anastesia Related
Known Adverse Events: Bradycardia | Apnea
Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|